Abstract：
OBJECTIVE: In Canada, plasma sent for fractionation is tested for both parvovirus B19 (B19V) and hepatitis A virus (HAV). This study compared positivity rates of B19 and HAV nucleic acid tests (NATs) in Canadian plasma samples for the pre-COVID-19 restriction era (2015 to end of February 2020 [Q1] 2020) and the post-COVID-19 restriction era.
METHODS: Pooled EDTA plasma specimens were tested within 24 months of blood draw using the Procleix Panther System (Grifols Diagnostic Solutions Inc, San Diego, CA, USA) for B19V and HAV detection. Reactive pools were resolved by individual specimen testing.
RESULTS: Between 1 January 2015, and 31 March 2022, 3,928,619 specimens from Canadian plasma donors were tested for B19V. For the same period, 3,922,954 specimens were tested for HAV. To account for a lag in specimen testing for up to 24 months, the data were divided into: (1) a pre-pandemic period (1 January 2015-31 March 2020; B19V tested n = 2,412,701, B19V NAT-positive n = 240 [0.01%], HAV tested n = 2,407,036, HAV NAT-positive n = 26 [0.001%]); (2) a two-year mixed-impact period (1 April 2020-31 March 2022; B19V tested n = 968,250, B19V NAT-positive n = 14 [0.001%], HAV tested n = 968,250, HAV NAT-positive n = 2 [0.0002%]); and (3) a pandemic-impact period (1 April 2022-31 March, 2023; B19V tested n = 597,668, B19V NAT-positive n = 3 [0.0005%], HAV tested n = 597,668, HAV NAT-positive n = 1 [0.0002%]).
CONCLUSIONS: The percentage of B19V- and HAV-positive donations was significantly reduced from the pre-pandemic period to the pandemic-impact period.
METHODS: Pooled EDTA plasma specimens were tested within 24 months of blood draw using the Procleix Panther System (Grifols Diagnostic Solutions Inc, San Diego, CA, USA) for B19V and HAV detection. Reactive pools were resolved by individual specimen testing.
RESULTS: Between 1 January 2015, and 31 March 2022, 3,928,619 specimens from Canadian plasma donors were tested for B19V. For the same period, 3,922,954 specimens were tested for HAV. To account for a lag in specimen testing for up to 24 months, the data were divided into: (1) a pre-pandemic period (1 January 2015-31 March 2020; B19V tested n = 2,412,701, B19V NAT-positive n = 240 [0.01%], HAV tested n = 2,407,036, HAV NAT-positive n = 26 [0.001%]); (2) a two-year mixed-impact period (1 April 2020-31 March 2022; B19V tested n = 968,250, B19V NAT-positive n = 14 [0.001%], HAV tested n = 968,250, HAV NAT-positive n = 2 [0.0002%]); and (3) a pandemic-impact period (1 April 2022-31 March, 2023; B19V tested n = 597,668, B19V NAT-positive n = 3 [0.0005%], HAV tested n = 597,668, HAV NAT-positive n = 1 [0.0002%]).
CONCLUSIONS: The percentage of B19V- and HAV-positive donations was significantly reduced from the pre-pandemic period to the pandemic-impact period.
摘要：
目标：在加拿大，对送去分级分离的血浆进行细小病毒B19(B19V)和甲型肝炎病毒(HAV)的检测。这项研究比较了加拿大血浆样本中COVID-19限制时代（2015年至2020年2月底[Q1]2020年）和COVID-19限制时代后的B19和HAV核酸检测（NAT）阳性率。
方法：使用ProcleixPanther系统（Grifols诊断解决方案公司，圣地亚哥,CA,美国)用于B19V和HAV检测。通过单独的样品测试解决了反应池。
结果：在2015年1月1日至2022年3月31日之间，对来自加拿大血浆供体的3,928,619份标本进行了B19V测试。在同一时期,对3,922,954个样本进行了HAV测试。考虑到样本测试的滞后长达24个月，数据分为：(1)大流行前时期(2015年1月1日至2020年3月31日；B19V测试n=2,412,701，B19VNAT阳性n=240[0.01%]，HAV测试n=2,407,036，HAVNAT阳性n=26[0.001%]）；（2）两年混合影响期（2020年4月1日至2022年3月31日；B19V测试n=968,250，B19VNAT阳性n=14[0.001%]，HAV测试n=968,250，HAVNAT阳性n=2[0.0002%])；和(3)大流行影响期(2022年4月1日至3月31日，2023年；B19V测试n=597,668，B19VNAT阳性n=3[0.0005%]，HAV测试n=597,668，HAVNAT阳性n=1[0.0002%])。
结论：从大流行前到大流行影响期，B19V和HAV阳性捐赠的百分比显着降低。
方法：使用ProcleixPanther系统（Grifols诊断解决方案公司，圣地亚哥,CA,美国)用于B19V和HAV检测。通过单独的样品测试解决了反应池。
结果：在2015年1月1日至2022年3月31日之间，对来自加拿大血浆供体的3,928,619份标本进行了B19V测试。在同一时期,对3,922,954个样本进行了HAV测试。考虑到样本测试的滞后长达24个月，数据分为：(1)大流行前时期(2015年1月1日至2020年3月31日；B19V测试n=2,412,701，B19VNAT阳性n=240[0.01%]，HAV测试n=2,407,036，HAVNAT阳性n=26[0.001%]）；（2）两年混合影响期（2020年4月1日至2022年3月31日；B19V测试n=968,250，B19VNAT阳性n=14[0.001%]，HAV测试n=968,250，HAVNAT阳性n=2[0.0002%])；和(3)大流行影响期(2022年4月1日至3月31日，2023年；B19V测试n=597,668，B19VNAT阳性n=3[0.0005%]，HAV测试n=597,668，HAVNAT阳性n=1[0.0002%])。
结论：从大流行前到大流行影响期，B19V和HAV阳性捐赠的百分比显着降低。
